查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602795

抗肥胖药物市场：依药物类型、作用机转划分 - 全球预测 2025-2030

Anti-Obesity Drugs Market by Drug Type (Over-The-Counter Drugs, Prescription Drugs), Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年抗肥胖药物市值为38.3亿美元，预计到2024年将达到40.9亿美元，复合年增长率为6.86%，到2030年将达到61亿美元。

抗肥胖药物市场范围包括旨在透过降低食慾、增加饱足感和抑制营养吸收来促进减肥的药物。随着全球肥胖率的迅速上升，有效的药物干预措施至关重要，不仅对于体重管理，而且对于降低糖尿病、心血管疾病和某些癌症等相关健康风险也变得非常重要。最终用途范围从医疗保健提供者和医院到零售药房和研究机构。

主要市场统计
基准年[2023] 38.3亿美元
预测年份 [2024] 40.9亿美元
预测年份 [2030] 61亿美元
复合年增长率（%） 6.86%

该市场的主要成长要素是人们对肥胖相关健康风险的认识不断提高、药物开发的技术进步以及政府倡导肥胖管理的支持政策。世界上越来越多的久坐生活方式和不健康的饮食模式进一步增加了对有效肥胖控制解决方案的需求。该领域的潜在机会包括根据基因图谱定制治疗的个人化医疗方法以及探索联合治疗以提高药物疗效。公司可以透过投资研发来开发更强大、副作用更少的药物并扩大其地理覆盖范围，特别是在肥胖率上升的新兴经济体，从而增强其市场地位。

市场开拓的挑战包括严格的监管核准、高昂的药物开发成本、潜在的药物副作用以及对肥胖治疗的社会耻辱。此外，由于大众对生活方式和手术治疗的偏好，对药物干预的怀疑限制了市场渗透。创新应着重于开发胰岛素增敏剂、针对肠道微生物群的药物，以及数位健康技术与药物治疗方案结合的机会，以提高患者的依从性和治疗结果。为了持续成长，为了强调综合治疗计划的重要性，强调药物有效性的现实证据，并消除公众对药物安全性和有效性的误解，公司应该鼓励与医疗保健提供者合作。市场仍然竞争激烈，要求公司透过策略伙伴关係和以患者为中心的创新不断发展。

市场动态：揭示快速发展的抗肥胖药物市场的关键市场洞察

供需的动态交互作用正在改变抗肥胖药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 肥胖和相关慢性疾病的负担增加
    • 不健康的速食和家常小菜的消费量迅速增加
    • 增强健康意识
  • 市场限制因素
    • 与药物相关的副作用
  • 市场机会
    • 提高人们对联合策略的认识
    • 减肥药的最新进展
  • 市场挑战
    • 市场上替代治疗方案的可用性

波特五力：驾驭抗肥胖药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗肥胖药物市场的外部影响

外部宏观环境因素在塑造抗肥胖药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗肥胖药物市场的竞争状况

抗肥胖药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗肥胖药物市场供应商绩效评估

FPNV定位矩阵是评估抗肥胖药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了抗肥胖药物市场的成功之路

抗肥胖药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肥胖和相关慢性疾病的负担日益增加
      • 快速食用不健康的速食和即食食品
      • 人们对健康和健身的兴趣日益浓厚
    • 抑制因素
      • 与药物相关的副作用
    • 机会
      • 对协作策略的认识不断增强
      • 肥胖症药物治疗的最新进展
    • 任务
      • 市场上替代治疗方案的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按类型分類的抗肥胖药物市场

  • 非处方药
  • 处方药

第七章依作用机转分類的抗肥胖药物市场

  • 中枢促效剂
  • 週边促效剂

第八章 北美和南美抗肥胖药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太抗肥胖药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲抗肥胖药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 6.86%, to USD 6.10 billion by 2030.

The scope of the anti-obesity drugs market encompasses pharmaceuticals designed to facilitate weight loss by reducing appetite, increasing satiety, or inhibiting nutrient absorption. With global obesity rates soaring, the necessity for effective pharmacological interventions has become critical, not only to manage weight but also to mitigate associated health risks like diabetes, cardiovascular diseases, and certain cancers. The primary applications include chronic weight management for patients with a significant body mass index (BMI), and the end-use scope ranges from healthcare providers and hospitals to retail pharmacies and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 3.83 billion
Estimated Year [2024] USD 4.09 billion
Forecast Year [2030] USD 6.10 billion
CAGR (%) 6.86%

Key growth factors in this market are driven by the increasing awareness of health risks linked to obesity, technological advancements in drug development, and supportive governmental policies advocating for obesity management. The rise in sedentary lifestyles and unhealthy diet patterns worldwide further escalates the need for effective anti-obesity solutions. Potential opportunities in this sector include personalized medicine approaches that tailor treatments based on genetic profiles and the exploration of combination therapies to enhance drug efficacy. Companies can strengthen their market position by investing in R&D to develop more potent drugs with fewer side effects and by expanding their geographical reach, especially in emerging economies where obesity rates are climbing.

Challenges impeding market growth consist of stringent regulatory approvals, high costs of drug development, potential side effects of medications, and societal stigma linked to obesity treatments. Moreover, market penetration is limited by public skepticism towards pharmacological interventions due to the preference for lifestyle and surgical treatments. Innovations should focus on developing insulin sensitizers, gut microbiota-targeting drugs, and opportunities for digital health technologies that integrate with drug regimens to improve patient adherence and outcomes. For sustained growth, businesses should foster collaborations with healthcare providers to emphasize the importance of comprehensive treatment plans, highlight real-world evidence of drug effectiveness, and address public misconceptions about medication safety and efficacy. The market's nature remains highly competitive, requiring firms to continuously evolve through strategic partnerships and patient-centric innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of obesity and related chronic diseases
    • Rapid consumption of unhealthy fast-foods and ready meals
    • Increasing inclination towards health & fitness
  • Market Restraints
    • Side-effects associated with drugs
  • Market Opportunities
    • Growing awareness among people with collaborative strategies
    • Recent advancements in drug treatment of obesity
  • Market Challenges
    • Availability of alternative treatment options in market

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Drugs Market

A detailed market share analysis in the Anti-Obesity Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Drugs Market

A strategic analysis of the Anti-Obesity Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus Inc..

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.
  • Based on Mechanism of Action, market is studied across Centrally Acting Drugs and Peripherally Acting Drugs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of obesity and related chronic diseases
      • 5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
      • 5.1.1.3. Increasing inclination towards health & fitness
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing awareness among people with collaborative strategies
      • 5.1.3.2. Recent advancements in drug treatment of obesity
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options in market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Obesity Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Drugs
  • 6.3. Prescription Drugs

7. Anti-Obesity Drugs Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Centrally Acting Drugs
  • 7.3. Peripherally Acting Drugs

8. Americas Anti-Obesity Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Boehringer Ingelheim International GmbH
  • 3. Bristol-Myers Squibb Company
  • 4. Currax Pharmaceuticals LLC
  • 5. Eisai Co. Ltd
  • 6. F. Hoffmann-La Roche AG
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co. Inc.
  • 9. Norgine BV
  • 10. Novo Nordisk AS
  • 11. Pfizer Inc.
  • 12. Rhythm Pharmaceuticals, Inc.
  • 13. SHIONOGI & Co., Ltd.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Vivus Inc.

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CENTRALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023